Showing posts with label Genetics. Show all posts
Showing posts with label Genetics. Show all posts

Sunday, 28 July 2013

Genetics and live cell imaging illuminate molecular mechanisms that position the cell division machinery in growing tissues

Main Category: Cancer / Oncology
Also Included In: Genetics
Article Date: 24 Jul 2013 - 0:00 PDT Current ratings for:
Genetics and live cell imaging illuminate molecular mechanisms that position the cell division machinery in growing tissues
not yet ratednot yet rated

Constructing a body is like building a house - if you compromise structural integrity, the edifice can collapse. Nowhere is that clearer on a cellular level than in the case of epithelial sheets, single layers of cells that line every body cavity from the gut to mammary glands. As long as epithelial cells pack tightly and adhere to their neighbors, the cellular business of building tissue barriers and constructing ducts goes smoothly. But if epithelial cells fail to hold together, they die, or worse, produce jumbled masses resembling tumors known collectively as carcinomas.

Stowers Institute for Medical Research Associate Investigator Matt Gibson, Ph.D., and his team use simple animal systems like fruit flies and sea anemones to investigate how epithelial cells maintain order while getting jostled by cell division.

New findings from his lab published in the advance online issue of Nature demonstrate that the way the mitotic spindle - the machinery that separates chromosomes into daughter cells during cell division - aligns relative to the surface of the cell layer is essential for the maintenance of epithelial integrity. It also hints at a surprising way that cells initiate a gene expression program seen in invasive cancers when that process goes awry.

The study employs live imaging of fruit fly imaginal discs, simple larval tissues that ultimately give rise to the adult wing. "In a culture dish, cells can divide willy nilly," says Gibson. "But in an organism cell division must be reconciled with the broader structural context. Our work is addressing how epithelial tissues maintain structural integrity, even during the extreme events of cell division."

The starting point for this work was the lab's 2011 Current Biology paper showing that when columnar cells packed in an epithelium divided, their upper (apical) end briefly ballooned out to allow the cell's nucleus to move into that region. As division began, the mitotic spindle (which faithfully distributes chromosomes into each daughter cell) invariably oriented itself parallel to the apical surface of the epithelium.

In other words, if you pointed a tiny camera in your gut toward dividing epithelial cells of its lining, you would "see" the mitotic spindle looking like a symmetrical web, exactly like it did in your high school biology textbook.

To determine why its orientation was non-random, the group did an equivalent experiment. Using high resolution fluorescence imaging to look inside dividing cells in developing wing discs, they observed that the two poles of the spindle were always near the septate junctions, specific regions of close molecular contact between neighboring cells. Two junction components, proteins called Discs Large and Scribble, were juxtaposed to the spindle, suggesting they might act as cues to orient it.

The seemingly odd names given to these factors decades ago reflect what biologists saw in fly mutants lacking each protein. In flies without Discs Large, the imaginal discs are massively overgrown, while fly embryos lacking Scribble resemble a chaotic scribble reminiscent of a tumor. Gibson reasoned that the reported tumor-suppressive activity of these proteins might be linked to a role in keeping the mitotic spindle in line.

So his group genetically deleted Scribble, Discs Large and a host of other factors in wing disc cells and watched what happened when cells divided, an effort aided by a customized microscope built by the Stowers Microscopy Center. What they saw was dramatic: Scribble deletion caused the mitotic spindle to flip over at a random angle, as did deletion of Discs Large. Next, by directly perturbing the spindle, the researchers video-captured the process by which cells with misoriented spindles began to peel away, or delaminate, from the epithelium.

"I did not expect that spindle orientation defects could be sufficient to cause loss of epithelial identity," explains Yu-ichiro Nakajima, Ph.D., a postdoctoral fellow in the Gibson lab and the study's first author. "But people in the field have hypothesized that spindle misorientation might cause tumorigenesis or even contribute to cancer development."

Initially, the group did not observe such dire consequences: Gibson says that delaminating cells generally "fall out of the epithelium" and are killed off by apoptosis, a mechanism healthy tissues use to eradicate damaged cells. But when the team experimentally inhibited apoptosis, tumor-like growths emerged at the base of the cell layer. Cells in those growths expressed genes switched on in invasive human tumors, among them the fruit fly version of human Matrix metalloproteinase-1, an epithelial cancer biomarker.

"The findings derived from epithelial biology often lead to a better understanding of cancer development," says Nakajima. "We have found that spindle orientation has a tumor-suppressive role in proliferating epithelia. So we are looking for other spindle regulators that may represent novel tumor suppressors."

Human epithelial cells do express mammalian Scribble and Discs Large proteins, and both play key roles in maintaining epithelial cell polarity, or shap - a property lost in metastatic cancer cells. Whether Scribble or Discs Large act as tumor suppressors in human cancers is under investigation.

Gibson urges caution in comparing regulation of Drosophila and human epithelia. Nonetheless he notes that normal tissues in both flies and humans protect themselves by killing off misbehaving cells via apoptosis. If that mechanism failed, as is frequently observed in human cancers, disordered cells within an epithelium could escape.

"When cells are basically imprisoned in an epithelial layer, things stay nicely organized," says Gibson. "But in this study we found that simply forcing a cell to delaminate from an epithelium is enough to initiate an abnormal gene expression program. That means that maintaining an ordered structure is not just a physical requirement but could also protects cells from switching on potentially aberrant genes."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject.

Other contributors were Emily Meyer from the Gibson lab, and Amanda Kroesen and Sean McKinney, Ph.D., from the Stowers Microscopy Center.

The study was funded by the Stowers Institute for Medical Research and the Burroughs Wellcome Fund.

Stowers Institute for Medical Research

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Stowers Institute for Medical Research. "Genetics and live cell imaging illuminate molecular mechanisms that position the cell division machinery in growing tissues." Medical News Today. MediLexicon, Intl., 24 Jul. 2013. Web.
24 Jul. 2013. APA
Stowers Institute for Medical Research. (2013, July 24). "Genetics and live cell imaging illuminate molecular mechanisms that position the cell division machinery in growing tissues." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/263744.php.

Please note: If no author information is provided, the source is cited instead.


'Genetics and live cell imaging illuminate molecular mechanisms that position the cell division machinery in growing tissues'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Friday, 12 July 2013

Patients With Aggressive Form Of Acute Lymphocytic Leukemia May Benefit From Advanced Genetics Technologies

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Genetics
Article Date: 11 Jul 2013 - 1:00 PDT Current ratings for:
Patients With Aggressive Form Of Acute Lymphocytic Leukemia May Benefit From Advanced Genetics Technologies
not yet ratednot yet rated

New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL). Study results were published online in Blood, the Journal of the American Society of Hematology (ASH).

Approximately 25 to 30 percent of all adults with ALL, the second most common type of acute leukemia, have what is known as Philadelphia chromosome-positive (Ph+) ALL, a rapidly progressing form of the disease caused by a genetic abnormality that is associated with a poor prognosis. Following their first complete remission, one of the most common preventive treatments Ph+ ALL patients undergo is an allogeneic stem cell transplant, in which a patient receives stem cells from a sibling or unrelated matched donor; however, this procedure can be associated with harsh side effects and may not be universally available. Some research conducted since the introduction and subsequent success of a new class of cancer drugs called tyrosine kinase inhibitors (TKIs), which target the abnormal, leukemia-causing protein BCR-ABL and have greatly improved survival rates, suggests that stem cell transplantation may not be necessary for some Ph+ ALL patients. However, clinicians lack a reliable method for predicting disease progression and determining whether a patient's disease is aggressive enough to warrant a stem cell transplant or if TKI therapy plus chemotherapy will likely eradicate the disease.

Despite the advent of these powerful, targeted cancer therapies, some cancer cells may linger in a patient's body following the primary course of treatment. However, data from several recent studies have suggested that monitoring the amount of this remaining cancer cell population, known as minimal residual disease (MRD), may be an effective indicator of a patient's risk of relapse. Consequently, clinicians have increasingly employed several highly sensitive monitoring tools to detect MRD, such as multi-parameter flow cytometry (MFC) and real-time quantitative polymerase chain reaction (RQ-PCR), that search for genetic aberrations in a patient's blood and bone marrow that indicate the presence of cancerous cells. Although this method has proved effective for several other types of leukemia, the reliability of these tools specific to Ph+ ALL is not yet fully understood.

"The arrival of tyrosine kinase inhibitors has marked the beginning of an exciting era in which we can begin considering alternative preventive cancer treatments and look to spare patients from the risk of toxicities that often accompany stem cell transplants," said lead study author Farhad Ravandi, MD, of The University of Texas MD Anderson Cancer Center in Houston. "Now that we know that these drugs are effective, we can take the next step and focus on studying lingering disease in Ph+ ALL patients to guide more effective treatments and ultimately predict and manage possible relapse."

To better understand how technology that tracks indicators of MRD could potentially predict Ph+ ALL patients' survival and inform treatment decisions, Dr. Ravandi and a team of MD Anderson researchers conducted a decade-long study to monitor whether a negative MRD reading was associated with prolonged survival. Between 2001 and 2011, Dr. Ravandi's team monitored 76 adult patients (average of 54 years old) with Ph+ ALL who had achieved complete remission after a treatment regimen including at least one course of induction chemotherapy plus a TKI followed by treatment with a TKI (either dasatinib or imatinib) and chemotherapy, and two years of TKI maintence therapy. All study participants began with fewer than 5 percent cancer cells in their body and none had undergone stem cell transplant, nor were they at an otherwise hightened risk of relapse. Utilizing MFC and RQ-PCR technologies, investigators monitored patients for MRD after first remission and every three months thereafter.

Results from the investigation suggested that when used together, MFC and RQ-PCR monitoring technologies were effective in predicting the majority of disease progression and patient outcomes in this population. Among 44 patients who showed evidence of MRD in the first year of follow-up (either by MFC or RQ-PCR results), 13 relapsed, including 9 of 22 of the highest risk patients who showed positive MFC at three months and beyond. Thirteen of 54 patients who maintained negative MRD from three months and beyond had relapsed.

While the MRD readings observed by Dr. Ravandi and his team did not accurately predict all patient outcomes in the study population, researchers note that these results indicate that the combination of MFC and RQ-PCR technologies represents a valuable prognostic tool to measure the likelihood of a patient relapse. However, researchers caution that it is too early to integrate the use of these technologies into treatment guidelines regarding the neccessity of stem cell transplant for Ph+ ALL patients.

"While our results aligned with our observed outcome in this study and the MFC and RQ-PCR technologies are very sensitive, these tools do not yet provide absolute results. We advise that each treatment decision be made on a patient-to-patient basis to take into account each patient's different genetics," said Dr. Ravandi. "The next step is to refine and standardize our approach to better define which patients are truly disease-free and who should be recommended for more aggressive treatment."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our lymphoma / leukemia / myeloma section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

American Society of Hematology. "Patients With Aggressive Form Of Acute Lymphocytic Leukemia May Benefit From Advanced Genetics Technologies." Medical News Today. MediLexicon, Intl., 11 Jul. 2013. Web.
11 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Patients With Aggressive Form Of Acute Lymphocytic Leukemia May Benefit From Advanced Genetics Technologies'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here